Health Care Regulation - Publications - Faculty & Research

06 May 2014
First Look

First Look: May 6

GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese View Details

Keywords: Sean Silverthorne

05 Aug 2015
What Do You Think?

What Happened to the ‘Innovation, Disruption, Technology’ Dividend?

W. Norton & Company, 2014). Martin Ford, Rise of the Robots: Technology and the Threat of a Jobless Future (New York: Basic Books, 2015). James L. Heskett, W. Earl Sasser, Jr., and Leonard A. Schlesinger, What Great Service Leaders Know and Do: Creating... View Details

Keywords: by James Heskett; Computer; Technology

May 2018
Case

The Multiple Myeloma Research Foundation's Answer Fund

By: Richard G. Hamermesh and Matthew G. Preble

Citation

Educators

18 Feb 2015
First Look

First Look: February 18

https://cb.hbsp.harvard.edu/cbmp/product/715411-PDF-ENG Harvard Business School Case 715-423 Discovery Limited Discovery Limited is a South-African based insurance company. Started in the early 1990s, Discovery used behavioral economics and data collection to innovate... View Details

Keywords: Sean Silverthorne

05 Jan 2010
First Look

First Look: January 5

leading center for diabetes care, clinician training, and research. The incidence of diabetes is rising precipitously worldwide, challenging quality of life with its complications and rapidly accelerating health View Details

Keywords: Martha Lagace

19 Feb 2019
First Look

New Research and Ideas, February 19, 2019

behavioral health economics, focusing on insurance markets and product markets in health care. We argue that the prevalence of choice difficulties and biases leading to mistakes in these markets establish a... View Details

Keywords: Sean Silverthorne

16 May 2017
First Look

First Look at New Ideas and Research, May 16

health of the enterprise rather than near-term returns to its shareholders. Their model would refocus companies’ attention to innovation, strategic renewal, and investment in the future. Publisher's link:... View Details

Keywords: Re: Multiple Faculty

October 2009 (Revised August 2014)
Case

Tengion: Bringing Regenerative Medicine to Life

By: Elie Ofek and Polly Ross Ribatt

Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details

Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States

Citation

Educators

Purchase

12 Mar 2014
Research & Ideas

Entrepreneurship and Multinationals Drive Globalization

War I, the management of political risk became a central concern for firms operating internationally. These risks were on many levels, from expropriation to exchange controls and other economic policies. The issue is explored in multiple chapters, but the chapter on... View Details

Keywords: by Sean Silverthorne; Beauty & Cosmetics; Manufacturing; Consumer Products; Pharmaceutical

17 Aug 2015
Research & Ideas

Who is Boss in the Sharing Economy?

negatively affecting each other's revenues—drivers poaching each other's fares, or stylists advertising against one another—then that would seem to tilt the balance in favor of the traditional business mode. "If the spillovers are negative, and the professionals only... View Details

Keywords: by Michael Blanding; Service; Technology

August 2008 (Revised May 2009)
Background Note

Note on Generic Drugs in the European Union

By: Robert C. Pozen and Elizabeth M. Leonard

Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details

Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States

Citation

Find at Harvard

August 2001
Case

Scios, Inc.

By: Regina E. Herzlinger

Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States

Citation

Educators

October 2021 (Revised January 2022)
Supplement

Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (C)

By: Linda A. Hill and Emily Tedards

This case is the third installment in a series about the 10-year cultural and digital transformation of Pfizer’s Global Clinical Supply organization. In 2011, Michael Ku became Pfizer’s Vice President of Global Clinical Supply (GCS) after the company had undergone... View Details

Keywords: Clinical Supply Chain; COVID-19; Vaccine; Agile; Innovation and Invention; Change Management; Organizational Culture; Transformation; Leadership; Corporate Strategy; Health Pandemics; Crisis Management; Mission and Purpose; Health Care and Treatment; Supply Chain Management; Digital Transformation

Citation

Purchase

06 Jan 2012
Op-Ed

Where Green Corporate Ratings Fail

News Corporation—a multinational media conglomerate that includes BSKYB, Dow Jones, Fox News, 20th Century Fox and Star, among other units—announced earlier this year that it has become climate neutral, meaning that its operations have no net impact on global climate... View Details

Keywords: by Michael Toffel & Auden Schendler; Information; Publishing

10 Jun 2014
First Look

First Look: June 10

political contributions. Even after the financial crisis, Wall Street was able to slow down and weaken new regulations meant to rein in its risky practices. This "financialization" of the economy has serious downsides: it... View Details

Keywords: Sean Silverthorne

October 2024
Article

Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates

By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini

Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated... View Details

Keywords: Insurance; Health Care and Treatment; Governing Rules, Regulations, and Reforms; United States

Citation

Find at Harvard

Purchase

March 2024
Article

Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act

By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti

The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details

Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry

Citation

Find at Harvard

Purchase

June 9, 2023
Article

A Radical Treatment for Insulin Pricing

By: Leemore S. Dafny

In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details

Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States

Citation

Find at Harvard

Register to Read

October 2009 (Revised July 2013)
Case

Gilead Sciences, Inc.: Access Program

By: V. Kasturi Rangan and Katharine Lee

Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details

Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Pharmaceutical Industry

Citation

Educators

Purchase